Short answer
IDEAYA Biosciences, Inc. (IDYA) filed its fiscal 2025 10-K annual report with the SEC on Feb 17, 2026. It reported revenue of $219M (+3024.4% year over year) and net income of −$114M.
- Top risk flagged: Regulatory risk: Servier License Agreement contract assets increased $6.0M, indicating dependency on this agreement's terms and regulatory compliance timing
FY2025 key financial metrics · XBRL
- Revenue
- $219M
- +3024.4% YoY
- Net income
- −$114M
- +58.6% YoY
- Operating margin
- -72.8%
- +4598.2 pp YoY
- EPS (diluted)
- −$1.28
- +61.9% YoY
- ROE
- -11.1%
- +14.8 pp YoY
- Operating cash flow
- −$71M
- +71.3% YoY
Source: XBRL data from the IDEAYA Biosciences, Inc. (IDYA) FY2025 10-K on SEC EDGAR. USD.
IDEAYA Biosciences, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core oncology precision medicine with focus on synthetic lethality and antibody-drug conjugates (ADCs) targeting molecularly defined solid tumors
- New Phase 3 neoadjuvant trial for darovasertib in primary uveal melanoma initiated, targeting eye preservation and vision improvement
- Servier exclusive license granted for darovasertib outside U.S., upfront payment $210M plus milestones up to $320M and royalties
- IDE849 DLL3 TOP1 ADC Phase 1 data in 100 patients shows 48% Grade 3+ TRAEs, median PFS 6.7 months, 83.3% ORR in brain metastasis at 2.4 mg/kg dose
- GSK terminating collaboration on Pol Theta inhibitor (IDE705) and WRN inhibitor (IDE275), programs transferring back for internal development
Management Discussion & Analysis
- Collaboration revenue $218.7M in 2025 vs $7.0M in 2024, up 3,024% driven by Servier License Agreement
- Net loss $113.7M in 2025 vs $274.5M in 2024; loss decreased 59%, operating expenses up 13% to $378.0M
- Research and development expenses $314.7M (+7%), general and administrative expenses $63.3M (+61%) in 2025
- Best performing segment: Collaboration revenue surge from Servier deal; worst: continued high R&D expenses, $98.1M on darovasertib
- Cash, cash equivalents, marketable securities $1.05B as of Dec 31, 2025; raised net $25M from equity ATM offering in 2025
- Outlook: Cash runway sufficient for 12+ months; expecting higher R&D expenses for clinical advancement; risk of funding shortfall if capital not raised
Risk Factors
- Regulatory risk: Servier License Agreement contract assets increased $6.0M, indicating dependency on this agreement's terms and regulatory compliance timing
- Macroeconomic threat: Operating cash used $71.1M in 2025 and $247.6M in 2024, showing high cash burn amid volatile financing environment
- Operational vulnerability: $10.4M accrued liabilities for CROs, CMOs, consultants, indicating heavy reliance on external research and manufacturing partners
- Financial risk: Net loss $113.7M in 2025 with $46.1M stock-based compensation, signaling significant operating losses and dilution risk
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.